A Phase 1/2 interventional study of ibrutinib and everolimus in Metastatic Renal Cell Carcinoma, Advanced Urothelial Carcinoma and Advanced Gastric Adenocarcinoma, sponsored by Pharmacyclics LLC.. Completed at 65 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-18.
Sponsored by Pharmacyclics LLC. (part of AbbVie) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,142 studies in Carcinoma, Renal Cell with a site in United States — 156 open to participants now, 280 under way, 26 of them phase 3. Carcinoma, Renal Cell · United States.
Among the 1,142 studies in Carcinoma, Renal Cell with a site in United States, this one is the 117th largest by enrollment of the 1,008 interventional ones that give a count, is one of 42 that started in 2015, is one of 146 in phase 1/2, and was the 600th registered.
2,039 studies on the registry are indexed under Carcinoma, Renal Cell; 395 are open to participants now.
Browse Carcinoma, Renal Cell studies →156 of the 1,142 studies in Carcinoma, Renal Cell with a site in United States are open now. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States
Ages 18+
University of Oklahoma · Sites in United States
Ages 18–100 · Men only
Roswell Park Cancer Institute · Sites in United States
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
Vanderbilt-Ingram Cancer Center · Sites in United States
Ages 18–100
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 307 Carcinoma, Renal Cell studies recruiting now, 254 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 20 take children under 18; 19 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,142 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 488 · Phase 2 529 · Phase 3 74 · Phase 4 10
First in 1990; this study’s year is marked. 42 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 263 is above the median of 43 across 1,565 interventional studies indexed under Carcinoma, Renal Cell.
Median enrollment 40 across the 1,008 interventional studies, 100 across the 87 observational. Of the 791 that completed or were terminated, 336 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
467 of 1,142 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pharmacyclics LLC., one of the names counted as AbbVie. Under that name alone:
Pharmacyclics LLC. is the lead sponsor of 54 studies on the registry; none are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 9 (90%) have results posted.
AbbVie has 5 studies filed under Carcinoma, Renal Cell — fewer than ten, so there is no comparison to draw.
98 of the studies in Carcinoma, Renal Cell with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03815643Phase 3EMD Serono Research & Development Institute, Inc.Avelumab Program Rollover Study | 2026-11-24 |
| NCT05678673Phase 3ExelixisStudy of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma | 2026-12-15 |
| NCT03592472Phase 3Xynomic Pharmaceuticals, Inc.A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV) | 2026-12-30 |
| NCT03873402Phase 3Bristol-Myers SquibbA Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer | 2027-03-11 |
| NCT05863351Phase 3ECOG-ACRIN Cancer Research GroupFocused Radiation Versus Systemic Therapy for Kidney Cancer Patients With Limited Metastasis, SOAR Study | 2027-08-31 |
Add all 98 to your calendar (.ics) → With an account.
Among the 1,142 studies in Carcinoma, Renal Cell with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety, tolerability, and efficacy of single agent ibrutinib or the combination treatments of ibrutinib with everolimus, paclitaxel, docetaxel, pembrolizumab or cetuximab in selected advance gastrointestinal and genitourinary tumors.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
RCC (clear cell), urothelial carcinoma (UC) (transitional cell), gastric or gastro-esophageal junctional (GEJ) adenocarcinoma, or K-RAS or N-RAS wild-type EGFR expressing CRC For cohort 1 RCC: minimum of 1 and maximum of 4 prior regimens, one or more of which must have included a VEGF-TKI For UC cohort 2: minimum of 1 and maximum of 2 prior regimens, one of which must have included a platinum-based regimen For UC cohort 5: Minimum of 1 and maximum of 2 prior regimens, one of which must have included a .
For UC cohort 6:
Locally advanced or mUC who are not eligible for cisplatin chemo with a PDL-1 score (CPS) of ≥ 10 without prior treatment.
Locally advanced or mUC who have progressed on platinum chemo or within 12 months of neo- or therapy with a platinum chemotherapy. A minimum of 1 and maximum of 2 prior therapies.
For cohort 3 gastric or GEJ adenocarcinoma: minimum of 1 and maximum of 3 prior regimens one of which must have included a fluoropyrimidine regimen For cohort 4 CRC: minimum of 2 and maximum of 4 prior regimens, which must have included both an irinotecan and an oxaliplatin based regimen unless unable to tolerate irinotecan chemotherapy
Laboratory:
Adequate hematologic function:
≥1500 cells/mm3 (1.5 x 109/L) count >80,000 cells/mm3 (80 x 109/L) for cohort 1 (RCC) Platelet counts >100,000 cells/mm3 (100 x 109/L) for all UC cohorts ≥8.0 g/dL. for cohort 1 (RCC),all UC cohorts, and cohort 3 (GC) Hemoglobin ≥9.0 g/dL for cohort 4 (CRC)
Adequate hepatic and renal function defined as:
Serum (AST) and/or alanine transaminase (ALT) ≤5.0 x (ULN) if liver , or ≤3 x ULN without liver metastases Alkaline phosphatase \<3.0 x ULN or ≤5.0 x ULN if liver or bone metastases present ≤1.5 x ULN (unless bilirubin rise is due to Gilbert's syndrome or of non-hepatic origin, such as hemolysis) with the exception of subjects in the GC cohort where docetaxel is administered, these subjects must have bilirubin within normal limits (WNL) Estimated ≥30 mL/min (Cockcroft-Gault)
Exclusion Criteria
Prior treatment with:
Everolimus or temsirolimus (RCC cohort 1) Any taxane (UC cohort of ibrutinib + paclitaxel) (cohort 2) (UC cohort 6) Any taxane (GC cohort 3) Cetuximab or panitumumab (CRC cohort 4)
For all Cohorts:
Concomitant use of warfarin or other Vitamin K antagonists History of stroke or intracranial hemorrhage within 6 months prior to enrollment Major surgery within 4 weeks of first dose of study drug Requires treatment with strong inhibitors known bleeding disorders or hemophilia
UC cohort 6 only:
Subjects who have an active, known or suspected disease. Evidence of interstitial lung disease or active, noninfectious pneumonitis.
Non- medications within 14 days before the first dose of ibrutinib and pembrolizumab.
Subjects in whom prior anti PD-1 / anti-PD-L1 therapy was intolerable and required discontinuation of treatment.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Phase 1b: Participants receive ibrutinib at various dose levels in combination with a fixed dose of everolimus to determine the recommended phase 2 dose (RP2D) of ibrutinib. (The RP2D was determined for each cohort separately.) Phase 2: Participants receive ibrutinib at the RP2D determined in phase 1b in combination with everolimus.
Drug: ibrutinib · Drug: everolimus
Phase 1b: Participants receive ibrutinib at various dose levels in combination with a fixed dose of paclitaxel to determine the RP2D of ibrutinib. (The RP2D was determined for each cohort separately.) Phase 2: Participants receive ibrutinib at the RP2D determined in Phase 1b in combination with paclitaxel.
Drug: ibrutinib · Drug: paclitaxel
Phase 1b: Participants receive ibrutinib at various dose levels in combination with a fixed dose of docetaxel to determine the RP2D of ibrutinib. (The RP2D was determined for each cohort separately.) Phase 2: Participants receive docetaxel at the RP2D determined in Phase 1b in combination with docetaxel.
Drug: ibrutinib · Drug: docetaxel
Phase 1b: Participants receive ibrutinib at various dose levels in combination with a fixed dose of cetuximab to determine RP2D of ibrutinib. (The RP2D was determined for each cohort separately.) Phase 2: Participants receive ibrutinib at the RP2D determined in Phase 1b in combination with cetuximab.
Drug: ibrutinib · Drug: cetuximab
Phase 1b: Participants receive ibrutinib at various dose levels to determine the RP2D of ibrutinib.(The RP2D was determined for each cohort separately.) Phase 2: Participants receive ibrutinib at the RP2D determined in Phase 1b.
Drug: ibrutinib
Phase 1b: Participants receive ibrutinib at various dose levels in combination with a fixed dose of pembrolizumab to determine the RP2D of ibrutinib. (The RP2D was determined for each cohort separately.) Phase 2: Participants receive ibrutinib at the RP2D determined in Phase 1b in combination with pembrolizumab.
Drug: ibrutinib · Drug: pembrolizumab
Ibrutinib administered orally once daily with 8 ounces (approximately 240 mL) of water.
Everolimus 10 mg tablets should be taken orally once daily at the same time every day, either consistently with food or consistently without food. Four (4) x 2.5 mg tablets or two (2) x 5.0 mg tablets may be substituted if 10 mg tablet strength is not available.
Paclitaxel should be administered as a 60-minute (±10 minutes) infusion. Paclitaxel should be given at a dose level of 80 mg/m\^2, once weekly, in continual 3 weekly cycles.
Docetaxel administered as a 60 minute infusion (±10 minutes) at a dose level of 60 - 75 mg/m\^2 (according to local institutional standard of care), given continually in 21-day cycles.
Cetuximab 400 mg/m\^2 administered as a 120-minute IV infusion. The recommended subsequent weekly dose (all other infusions) is 250 mg/m\^2 infused over 60 minutes.
Pembrolizumab 200 mg intravenous (IV) every 3 weeks.
Phase 1b: Number of Participants With Dose-Limiting Toxicities (DLTs) in Cohorts 1 to 6
A DLT was defined as any Grade 3 (severe) or higher non-hematologic or Grade 4 (life-threatening) hematologic adverse event (AE) occurring during the DLT observation period that was considered to be at least possibly related to the study treatment (ibrutinib or drug combination).
Time frame: 21 days after the initiation of therapy at the start of Cycle 1
Phase 1b/2 RP2D: Progression-Free Survival (PFS) as Assessed by Investigator in Cohorts 1 and 2
PFS is defined as the time from the date of first dose of study treatment to the date of first documentation of progressive disease (PD) or date of death from any cause, whichever occurs first, regardless of the use of subsequent anti-cancer treatment. PD was defined in accordance with Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.1. PD: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study), and an absolute increase of ≥ 5 mm, or unequivocal progression of existing non-target lesions or the appearance of new lesions.
Time frame: Maximum time on study for Cohort 1 (Phase 1b/2 RP2D) was 37.4 months; for Cohort 2 (Phase 1b/2 RP2D) was 44.7 months.
Phase 1b/2 RP2D: Overall Response Rate (ORR) as Assessed by Investigator in Cohorts 3 to 6
ORR is defined as the percentage of participants who have a best response of partial response (PR) or complete response (CR) to therapy in accordance with RECIST 1.1 criteria. CR: The disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Normalization of tumor marker level, if relevant. All lymph nodes must be non-pathological in size (\< 10 mm short axis). PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: Maximum time on study (Phase 1b/2 RP2D) for Cohort 3 was 41.9 months; for Cohort 4 was 23.5 months; for Cohort 5 was 17.3 months; for Cohort 6 was 20.1 months.
Phase 1b: ORR in Cohorts 1 to 6
ORR is defined as the percentage of participants who have a best response of partial response (PR) or complete response (CR) to therapy in accordance with RECIST 1.1 criteria. CR: The disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Normalization of tumor marker level, if relevant. All lymph nodes must be non-pathological in size (\< 10 mm short axis). PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: Maximum time on study (Phase 1b only) for Cohort 1 was 37.4 months; for Cohort 2 was 44.7 months; for Cohort 3 was 41.9 months; for Cohort 4 was 34.2 months; for Cohort 5 was 17.3 months; for Cohort 6 was 20.1 months.
Phase 1b: Disease Control Rate (DCR) in Cohorts 1 to 6
DCR is is defined as the percentage of participants who have a best response of PR, CR, or stable disease (SD) to therapy in accordance with RECIST 1.1 criteria. CR: The disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Normalization of tumor marker level, if relevant. All lymph nodes must be non-pathological in size (\< 10 mm short axis). PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest SOD since the treatment started (baseline or after). For SD, tthere was no need for confirmation by a subsequent imaging assessment.
Time frame: Maximum time on study (Phase 1b only) for Cohort 1 was 37.4 months; for Cohort 2 was 44.7 months; for Cohort 3 was 41.9 months; for Cohort 4 was 34.2 months; for Cohort 5 was 17.3 months; for Cohort 6 was 20.1 months.
Phase 1b/2 RP2D: DCR in Cohorts 1 to 6
DCR is is defined as the percentage of participants who have a best response of PR, CR, or SD to therapy in accordance with RECIST 1.1 criteria. CR: The disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Normalization of tumor marker level, if relevant. All lymph nodes must be non-pathological in size (\< 10 mm short axis). PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest SOD since the treatment started (baseline or after). For SD, tthere was no need for confirmation by a subsequent imaging assessment.
Time frame: Maximum time on study (Phase 1b/2 RP2D) for Cohort 1 was 37.4 months; for Cohort 2 was 44.7 months; for Cohort 3 was 41.9 months; for Cohort 4 was 23.5 months; for Cohort 5 was 17.3 months; for Cohort 6 was 20.1 months. (Reverse Kaplan-Meier estimates)
Phase 1b/2 RP2D: PFS in Cohorts 3 to 6
PFS is defined as the time from the date of first dose of study treatment to the date of first documentation of PD or date of death from any cause, whichever occurs first, regardless of the use of subsequent anti-cancer treatment. PD was defined in accordance with RECIST 1.1 criteria.
Time frame: Maximum time on study (Phase 1b/2 RP2D) for Cohort 3 was 41.9 months; for Cohort 4 was 23.5 months; for Cohort 5 was 17.3 months; for Cohort 6 was 20.1 months. (Reverse Kaplan-Meier estimates)
Phase 1b/2 RP2D: ORR in Cohorts 1 and 2
ORR is defined as the percentage of participants who have a best response to therapy of PR or CR in accordance with RECIST 1.1 criteria. CR: The disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Normalization of tumor marker level, if relevant. All lymph nodes must be non-pathological in size (\< 10 mm short axis). PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: Maximum time on study for Cohort 1 (Phase 1b/2 RP2D) was 37.4 months; for Cohort 2 (Phase 1b/2 RP2D) was 44.7 months. (Reverse Kaplan-Meier estimates)
Phase 1b/2 RP2D: Overall Survival (OS) in Cohorts 1 to 6
OS is defined as the time from the date of first dose of study treatment to the date of death from any cause. Subjects who were not known to have died at the data extraction will be censored at date last known alive.
Time frame: Maximum time on study (Phase 1b/2 RP2D) for Cohort 1 was 37.4 months; for Cohort 2 was 44.7 months; for Cohort 3 was 41.9 months; for Cohort 4 was 23.5 months; for Cohort 5 was 17.3 months; for Cohort 6 was 20.1 months. (Reverse Kaplan-Meier estimates)
Phase 1b/2 RP2D: Duration of Response (DOR) in Cohorts 1 to 6
DOR is defined for confirmed responders (PR or better) as time from the date of initial response (PR or better) to the date of first documentation of PD (according to RECIST 1.1) or death, whichever occurs first, regardless of use of subsequent anti-cancer treatment. Confirmed responders without documentation of PD or death or with unknown status at the data extraction were censored at the last adequate post-baseline disease assessment showing no evidence of PD. PD was defined as at least a 20% increase in the size of target lesions with an absolute increase of at least 5 mm, unequivocal progression of existing non-target lesions, or the appearance of one or more new lesions. Per protocol, participants in Phase 1b receiving the Phase 2 RP2D and participants in Phase 2 RP2D were analyzed together.
Time frame: Maximum time on study (Phase 1b/2 RP2D) for Cohort 1 was 37.4 months; for Cohort 2 was 44.7 months; for Cohort 3 was 41.9 months; for Cohort 4 was 23.5 months; for Cohort 5 was 17.3 months; for Cohort 6 was 20.1 months. (Reverse Kaplan-Meier estimates)
Phase 1b: Observed Maximum Concentration (Cmax) for Ibrutinib and Its Metabolite PCI-45227 in Cohorts 1 to 4
Actual collection times relative to ibrutinib administration were used for the calculation of pharmacokinetic parameters of ibrutinib and PCI-45227. For actual predose collection times that were \< 0, these values were set equal to 0. Predose concentrations were applied as 24 hour concentrations in order to calculate steady-state (Cycle 2 Day 1) pharmacokinetic parameters for ibrutinib and PCI-45227. The Cmax was noted as observed.
Time frame: Cycle 2 Day 1: predose, 1 h ± 15 min, 2 h ± 15 min, 4 h ± 15 min, 6 h ± 15 min postdose
Phase 1b: Time to Cmax (Tmax) for Ibrutinib and Its Metabolite PCI-45227 in Cohorts 1 to 4
Actual collection times relative to ibrutinib administration were used for the calculation of pharmacokinetic parameters of ibrutinib and PCI-45227. For actual predose collection times that were \< 0, these values were set equal to 0. Predose concentrations were applied as 24 hour concentrations in order to calculate steady-state (Cycle 2 Day 1) pharmacokinetic parameters for ibrutinib and PCI-45227. The tmax was noted as observed.
Time frame: Cycle 2 Day 1: predose, 1 h ± 15 min, 2 h ± 15 min, 4 h ± 15 min, 6 h ± 15 min postdose
Phase 1b: Time of Last Observed Concentration (Tlast) for Ibrutinib and Its Metabolite PCI-45227 in Cohorts 1 to 4
Actual collection times relative to ibrutinib administration were used for the calculation of pharmacokinetic parameters of ibrutinib and PCI-45227. For actual predose collection times that were \< 0, these values were set equal to 0. Predose concentrations were applied as 24 hour concentrations in order to calculate steady-state (Cycle 2 Day 1) pharmacokinetic parameters for ibrutinib and PCI-45227. The tlast was noted as observed.
Time frame: Cycle 2 Day 1: predose, 1 h ± 15 min, 2 h ± 15 min, 4 h ± 15 min, 6 h ± 15 min postdose
Phase 1b: Area Under the Concentration-Time Curve From Time 0 to Hour 24 (AUC0-24h) for Ibrutinib and Its Metabolite PCI-45227 in Cohorts 1 to 4
Actual collection times relative to ibrutinib administration were used for the calculation of pharmacokinetic parameters of ibrutinib and PCI-45227. For actual predose collection times that were \< 0, these values were set equal to 0. Predose concentrations were applied as 24 hour concentrations in order to calculate steady-state (Cycle 2 Day 1) pharmacokinetic parameters for ibrutinib and PCI-45227. The AUC0-24h was calculated by the linear trapezoidal method.
Time frame: Cycle 2 Day 1: predose, 1 h ± 15 min, 2 h ± 15 min, 4 h ± 15 min, 6 h ± 15 min postdose
Phase 1b: Area Under the Concentration-Time Curve to Last Observed Time Point (AUClast) for Ibrutinib and Its Metabolite PCI-45227 in Cohorts 1 to 4
Actual collection times relative to ibrutinib administration were used for the calculation of pharmacokinetic parameters of ibrutinib and PCI-45227. For actual predose collection times that were \< 0, these values were set equal to 0. Predose concentrations were applied as 24 hour concentrations in order to calculate steady-state (Cycle 2 Day 1) pharmacokinetic parameters for ibrutinib and PCI-45227. The AUClast was calculated by the linear trapezoidal method.
Time frame: Cycle 2 Day 1: predose, 1 h ± 15 min, 2 h ± 15 min, 4 h ± 15 min, 6 h ± 15 min postdose
Phase 1b: Terminal Elimination Half-Life (t1/2term) for Ibrutinib and Its Metabolite PCI-45227 in Cohorts 1 to 4
Actual collection times relative to ibrutinib administration were used for the calculation of pharmacokinetic parameters of ibrutinib and PCI-45227. For actual predose collection times that were \< 0, these values were set equal to 0. Predose concentrations were applied as 24 hour concentrations in order to calculate steady-state (Cycle 2 Day 1) pharmacokinetic parameters for ibrutinib and PCI-45227. The apparent t1/2term was calculated by ln(2)/λz, where λz is the apparent elimination rate constant obtained by linear regression of three or more log-transformed data points in the terminal phase (not including Cmax).
Time frame: Cycle 2 Day 1: predose, 1 h ± 15 min, 2 h ± 15 min, 4 h ± 15 min, 6 h ± 15 min postdose
Phase 1b: Terminal Elimination Rate Constant (λz) for Ibrutinib and Its Metabolite PCI-45227 in Cohorts 1 to 4
Actual collection times relative to ibrutinib administration were used for the calculation of pharmacokinetic parameters of ibrutinib and PCI-45227. For actual predose collection times that were \< 0, these values were set equal to 0. Predose concentrations were applied as 24 hour concentrations in order to calculate steady-state (Cycle 2 Day 1) pharmacokinetic parameters for ibrutinib and PCI-45227. The λz is the apparent elimination rate constant obtained by linear regression of three or more log-transformed data points in the terminal phase (not including Cmax).
Time frame: Cycle 2 Day 1: predose, 1 h ± 15 min, 2 h ± 15 min, 4 h ± 15 min, 6 h ± 15 min postdose
Phase 1b: Apparent Total Clearance at Steady-State (CLss/F) for Ibrutinib in Cohorts 1 to 4
Actual collection times relative to ibrutinib administration were used for the calculation of pharmacokinetic parameters of ibrutinib and PCI-45227. For actual predose collection times that were \< 0, these values were set equal to 0. Predose concentrations were applied as 24 hour concentrations in order to calculate steady-state (Cycle 2 Day 1) pharmacokinetic parameters for ibrutinib and PCI-45227. Apparent total CLss/F (Cycle 2 Day 1) was calculated as dose/AUC0-24h.
Time frame: Cycle 2 Day 1: predose, 1 h ± 15 min, 2 h ± 15 min, 4 h ± 15 min, 6 h ± 15 min postdose
In Phase 1b, participants were enrolled into 6 separate cohorts according to clinical indication: renal cell carcinoma (RCC; Cohort 1), urothelial carcinoma (UC; Cohort 2), gastric adenocarcinoma (GA; Cohort 3), colorectal adenocarcinoma (CRC; Cohort 4), urothelial carcinoma (UC; Cohorts 5 and 6). A dose level review committee (DLRC) evaluated the safety data at the completion of Phase 1b in each cohort to determine the recommended Phase 2 dose (RP2D), with the exception of Cohort 5.
| Milestone | Cohort 1 (RCC): Ibrutinib 560 mg + Everolimus | Cohort 1 (RCC): Ibrutinib 840 mg + Everolimus | Cohort 2 (UC): Ibrutinib 560 mg + Paclitaxel | Cohort 2 (UC): Ibrutinib 840 mg + Paclitaxel | Cohort 3 (GA): Ibrutinib 560 mg + Docetaxel | Cohort 4 (CRC): Ibrutinib 560 mg + Cetuximab | Cohort 4 (CRC): Ibrutinib 840 mg + Cetuximab | Cohort 5 (UC): Ibrutinib 840 mg | Cohort 6 (UC): Ibrutinib 560 mg + Pembrolizumab |
|---|---|---|---|---|---|---|---|---|---|
| Started | 3 | 7 | 4 | 10 | 21 | 8 | 12 | 10 | 17 |
| Completed | 3 | 7 | 4 | 10 | 21 | 8 | 12 | 10 | 17 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Cohort 1 (RCC): Ibrutinib 560 mg + Everolimus | Cohort 1 (RCC): Ibrutinib 840 mg + Everolimus | Cohort 2 (UC): Ibrutinib 560 mg + Paclitaxel | Cohort 2 (UC): Ibrutinib 840 mg + Paclitaxel | Cohort 3 (GA): Ibrutinib 560 mg + Docetaxel | Cohort 4 (CRC): Ibrutinib 560 mg + Cetuximab | Cohort 4 (CRC): Ibrutinib 840 mg + Cetuximab | Cohort 5 (UC): Ibrutinib 840 mg | Cohort 6 (UC): Ibrutinib 560 mg + Pembrolizumab |
|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 38 | 0 | 55 | 31 | 0 | 44 | 33 | 13 |
| Continued from phase 1b | 0 | 6 | 0 | 6 | 6 | 0 | 6 | 8 | 12 |
| Enrolled in phase 2 | 0 | 32 | 0 | 49 | 25 | 0 | 39 | 25 | 1 |
| Enrolled and treated in phase 2 | 0 | 32 | 0 | 49 | 25 | 0 | 38 | 25 | 1 |
| Completed | 0 | 38 | 0 | 55 | 31 | 0 | 44 | 33 | 13 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
A DLT was defined as any Grade 3 (severe) or higher non-hematologic or Grade 4 (life-threatening) hematologic adverse event (AE) occurring during the DLT observation period that was considered to be at least possibly related to the study treatment (ibrutinib or drug combination).
| Participants | Cohort 1 (RCC): Ibrutinib 560 mg + Everolimus | Cohort 1 (RCC): Ibrutinib 840 mg + Everolimus | Cohort 2 (UC): Ibrutinib 560 mg + Paclitaxel | Cohort 2 (UC): Ibrutinib 840 mg + Paclitaxel | Cohort 3 (GA): Ibrutinib 560 mg + Docetaxel | Cohort 4 (CRC): Ibrutinib 560 mg + Cetuximab | Cohort 4 (CRC): Ibrutinib 840 mg + Cetuximab | Cohort 5 (UC): Ibrutinib 840 mg | Cohort 6 (UC): Ibrutinib 560 mg + Pembrolizumab |
|---|---|---|---|---|---|---|---|---|---|
| Phase 1b: Number of Participants With Dose-Limiting Toxicities (DLTs) in Cohorts 1 to 6 | 0 | 1 | 0 | 0 | 2 | 0 | 0 | 0 | 0 |
PFS is defined as the time from the date of first dose of study treatment to the date of first documentation of progressive disease (PD) or date of death from any cause, whichever occurs first, regardless of the use of subsequent anti-cancer treatment. PD was defined in accordance with Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.1. PD: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study), and an absolute increase of ≥ 5 mm, or unequivocal progression of existing non-target lesions or the appearance of new lesions.
| months | Cohort 1 (RCC): Ibrutinib 840 mg + Everolimus | Cohort 2 (UC): Ibrutinib 840 mg + Paclitaxel |
|---|---|---|
| Phase 1b/2 RP2D: Progression-Free Survival (PFS) as Assessed by Investigator in Cohorts 1 and 2 | 5.6 (3.9 to 7.5) | 4.1 (2.7 to 4.4) |
ORR is defined as the percentage of participants who have a best response of partial response (PR) or complete response (CR) to therapy in accordance with RECIST 1.1 criteria. CR: The disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Normalization of tumor marker level, if relevant. All lymph nodes must be non-pathological in size (\< 10 mm short axis). PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
| percentage of participants | Cohort 3 (GA): Ibrutinib 560 mg + Docetaxel | Cohort 4 (CRC): Ibrutinib 840 mg + Cetuximab | Cohort 5 (UC): Ibrutinib 840 mg | Cohort 6 (UC): Ibrutinib 560 mg + Pembrolizumab |
|---|---|---|---|---|
| Phase 1b/2 RP2D: Overall Response Rate (ORR) as Assessed by Investigator in Cohorts 3 to 6 | 17.9 (8.7 to 31.1) | 14.9 (7.2 to 26.2) | 6.9 (1.2 to 20.2) | 35.7 (15.3 to 61.0) |
ORR is defined as the percentage of participants who have a best response of partial response (PR) or complete response (CR) to therapy in accordance with RECIST 1.1 criteria. CR: The disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Normalization of tumor marker level, if relevant. All lymph nodes must be non-pathological in size (\< 10 mm short axis). PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
| percentage of participants | Cohort 1 (RCC): Ibrutinib 560 mg + Everolimus | Cohort 1 (RCC): Ibrutinib 840 mg + Everolimus | Cohort 2 (UC): Ibrutinib 560 mg + Paclitaxel | Cohort 2 (UC): Ibrutinib 840 mg + Paclitaxel | Cohort 3 (GA): Ibrutinib 560 mg + Docetaxel | Cohort 4 (CRC): Ibrutinib 560 mg + Cetuximab | Cohort 4 (CRC): Ibrutinib 840 mg + Cetuximab | Cohort 5 (UC): Ibrutinib 840 mg | Cohort 6 (UC): Ibrutinib 560 mg + Pembrolizumab |
|---|---|---|---|---|---|---|---|---|---|
| Phase 1b: ORR in Cohorts 1 to 6 | 0 (0.0 to 63.2) | 0 (0.0 to 34.8) | 50.0 (9.8 to 90.2) | 20.0 (3.7 to 50.7) | 11.1 (2.0 to 31.0) | 12.5 (0.6 to 47.1) | 0 (0.0 to 25.9) | 12.5 (0.6 to 47.1) | 38.5 (16.6 to 64.5) |
DCR is is defined as the percentage of participants who have a best response of PR, CR, or stable disease (SD) to therapy in accordance with RECIST 1.1 criteria. CR: The disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Normalization of tumor marker level, if relevant. All lymph nodes must be non-pathological in size (\< 10 mm short axis). PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest SOD since the treatment started (baseline or after). For SD, tthere was no need for confirmation by a subsequent imaging assessment.
| percentage of participants | Cohort 1 (RCC): Ibrutinib 560 mg + Everolimus | Cohort 1 (RCC): Ibrutinib 840 mg + Everolimus | Cohort 2 (UC): Ibrutinib 560 mg + Paclitaxel | Cohort 2 (UC): Ibrutinib 840 mg + Paclitaxel | Cohort 3 (GA): Ibrutinib 560 mg + Docetaxel | Cohort 4 (CRC): Ibrutinib 560 mg + Cetuximab | Cohort 4 (CRC): Ibrutinib 840 mg + Cetuximab | Cohort 5 (UC): Ibrutinib 840 mg | Cohort 6 (UC): Ibrutinib 560 mg + Pembrolizumab |
|---|---|---|---|---|---|---|---|---|---|
| Phase 1b: Disease Control Rate (DCR) in Cohorts 1 to 6 | 66.7 (13.5 to 98.3) | 71.4 (34.1 to 94.7) | 75.0 (24.9 to 98.7) | 50.0 (22.2 to 77.8) | 77.8 (56.1 to 92.0) | 75.0 (40.0 to 95.4) | 80.0 (49.3 to 96.3) | 37.5 (11.1 to 71.1) | 76.9 (50.5 to 93.4) |
DCR is is defined as the percentage of participants who have a best response of PR, CR, or SD to therapy in accordance with RECIST 1.1 criteria. CR: The disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Normalization of tumor marker level, if relevant. All lymph nodes must be non-pathological in size (\< 10 mm short axis). PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest SOD since the treatment started (baseline or after). For SD, tthere was no need for confirmation by a subsequent imaging assessment.
| percentage of participants | Cohort 1 (RCC): Ibrutinib 840 mg + Everolimus | Cohort 2 (UC): Ibrutinib 840 mg + Paclitaxel | Cohort 3 (GA): Ibrutinib 560 mg + Docetaxel | Cohort 4 (CRC): Ibrutinib 840 mg + Cetuximab | Cohort 5 (UC): Ibrutinib 840 mg | Cohort 6 (UC): Ibrutinib 560 mg + Pembrolizumab |
|---|---|---|---|---|---|---|
| Phase 1b/2 RP2D: DCR in Cohorts 1 to 6 | 80.6 (66.6 to 90.5) | 66.7 (55.0 to 77.0) | 74.4 (60.4 to 85.4) | 83.0 (71.4 to 91.2) | 48.3 (32.0 to 64.8) | 71.4 (46.0 to 89.6) |
PFS is defined as the time from the date of first dose of study treatment to the date of first documentation of PD or date of death from any cause, whichever occurs first, regardless of the use of subsequent anti-cancer treatment. PD was defined in accordance with RECIST 1.1 criteria.
| months | Cohort 3 (GA): Ibrutinib 560 mg + Docetaxel | Cohort 4 (CRC): Ibrutinib 840 mg + Cetuximab | Cohort 5 (UC): Ibrutinib 840 mg | Cohort 6 (UC): Ibrutinib 560 mg + Pembrolizumab |
|---|---|---|---|---|
| Phase 1b/2 RP2D: PFS in Cohorts 3 to 6 | 4.0 (2.7 to 4.2) | 5.4 (4.1 to 5.8) | 1.6 (1.4 to 2.5) | 2.9 (1.7 to NA) |
ORR is defined as the percentage of participants who have a best response to therapy of PR or CR in accordance with RECIST 1.1 criteria. CR: The disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Normalization of tumor marker level, if relevant. All lymph nodes must be non-pathological in size (\< 10 mm short axis). PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
| percentage of participants | Cohort 1 (RCC): Ibrutinib 840 mg + Everolimus | Cohort 2 (UC): Ibrutinib 840 mg + Paclitaxel |
|---|---|---|
| Phase 1b/2 RP2D: ORR in Cohorts 1 and 2 | 2.8 (0.1 to 12.5) | 26.3 (17.0 to 37.6) |
OS is defined as the time from the date of first dose of study treatment to the date of death from any cause. Subjects who were not known to have died at the data extraction will be censored at date last known alive.
| months | Cohort 1 (RCC): Ibrutinib 840 mg + Everolimus | Cohort 2 (UC): Ibrutinib 840 mg + Paclitaxel | Cohort 3 (GA): Ibrutinib 560 mg + Docetaxel | Cohort 4 (CRC): Ibrutinib 840 mg + Cetuximab | Cohort 5 (UC): Ibrutinib 840 mg | Cohort 6 (UC): Ibrutinib 560 mg + Pembrolizumab |
|---|---|---|---|---|---|---|
| Phase 1b/2 RP2D: Overall Survival (OS) in Cohorts 1 to 6 | 21.0 (13.1 to 25.3) | 8.2 (6.2 to 10.3) | 7.3 (5.5 to 9.6) | 15.0 (10.5 to 17.2) | 8.2 (4.4 to NA) | 15.7 (7.7 to NA) |
DOR is defined for confirmed responders (PR or better) as time from the date of initial response (PR or better) to the date of first documentation of PD (according to RECIST 1.1) or death, whichever occurs first, regardless of use of subsequent anti-cancer treatment. Confirmed responders without documentation of PD or death or with unknown status at the data extraction were censored at the last adequate post-baseline disease assessment showing no evidence of PD. PD was defined as at least a 20% increase in the size of target lesions with an absolute increase of at least 5 mm, unequivocal progression of existing non-target lesions, or the appearance of one or more new lesions. Per protocol, participants in Phase 1b receiving the Phase 2 RP2D and participants in Phase 2 RP2D were analyzed together.
| months | Cohort 1 (RCC): Ibrutinib 840 mg + Everolimus | Cohort 2 (UC): Ibrutinib 840 mg + Paclitaxel | Cohort 3 (GA): Ibrutinib 560 mg + Docetaxel | Cohort 4 (CRC): Ibrutinib 840 mg + Cetuximab | Cohort 5 (UC): Ibrutinib 840 mg | Cohort 6 (UC): Ibrutinib 560 mg + Pembrolizumab |
|---|---|---|---|---|---|---|
| Phase 1b/2 RP2D: Duration of Response (DOR) in Cohorts 1 to 6 | 3.1 (NA to NA) | 4.4 (3.1 to 6.8) | 5.5 (3.0 to 18.0) | 11.1 (4.2 to 12.5) | 3.5 (3.1 to NA) | NA (2.6 to NA) |
Actual collection times relative to ibrutinib administration were used for the calculation of pharmacokinetic parameters of ibrutinib and PCI-45227. For actual predose collection times that were \< 0, these values were set equal to 0. Predose concentrations were applied as 24 hour concentrations in order to calculate steady-state (Cycle 2 Day 1) pharmacokinetic parameters for ibrutinib and PCI-45227. The Cmax was noted as observed.
| ng/mL | Cohort 1 (RCC): Ibrutinib 560 mg + Everolimus | Cohort 1 (RCC): Ibrutinib 840 mg + Everolimus | Cohort 2 (UC): Ibrutinib 560 mg + Paclitaxel | Cohort 2 (UC): Ibrutinib 840 mg + Paclitaxel | Cohort 3 (GA): Ibrutinib 560 mg + Docetaxel | Cohort 4 (CRC): Ibrutinib 560 mg + Cetuximab | Cohort 4 (CRC): Ibrutinib 840 mg + Cetuximab |
|---|---|---|---|---|---|---|---|
| Ibrutininb | 172 ± 188 | 351 ± 247 | 260 ± 287 | 424 ± 319 | 164 ± 193 | 172 ± 116 | 371 ± 270 |
| PCI-45227 | 51.2 ± 50.0 | 147 ± 77.6 | 127 ± 74.0 | 198 ± 106 | 106 ± 64.6 | 154 ± 76.1 | 177 ± 98.9 |
Actual collection times relative to ibrutinib administration were used for the calculation of pharmacokinetic parameters of ibrutinib and PCI-45227. For actual predose collection times that were \< 0, these values were set equal to 0. Predose concentrations were applied as 24 hour concentrations in order to calculate steady-state (Cycle 2 Day 1) pharmacokinetic parameters for ibrutinib and PCI-45227. The tmax was noted as observed.
| hours | Cohort 1 (RCC): Ibrutinib 560 mg + Everolimus | Cohort 1 (RCC): Ibrutinib 840 mg + Everolimus | Cohort 2 (UC): Ibrutinib 560 mg + Paclitaxel | Cohort 2 (UC): Ibrutinib 840 mg + Paclitaxel | Cohort 3 (GA): Ibrutinib 560 mg + Docetaxel | Cohort 4 (CRC): Ibrutinib 560 mg + Cetuximab | Cohort 4 (CRC): Ibrutinib 840 mg + Cetuximab |
|---|---|---|---|---|---|---|---|
| Ibrutininb | 3.01 (1.03 to 4.00) | 2.00 (0.933 to 5.90) | 3.71 (1.00 to 6.00) | 4.00 (0.833 to 6.00) | 3.89 (0.917 to 6.10) | 2.89 (1.00 to 4.08) | 2.03 (0.967 to 24.0) |
| PCI-45227 | 3.03 (1.03 to 6.02) | 3.93 (1.00 to 5.90) | 4.00 (2.00 to 6.00) | 4.00 (1.00 to 6.00) | 4.00 (0.917 to 6.10) | 2.99 (1.25 to 4.08) | 4.00 (0.967 to 24.0) |
Actual collection times relative to ibrutinib administration were used for the calculation of pharmacokinetic parameters of ibrutinib and PCI-45227. For actual predose collection times that were \< 0, these values were set equal to 0. Predose concentrations were applied as 24 hour concentrations in order to calculate steady-state (Cycle 2 Day 1) pharmacokinetic parameters for ibrutinib and PCI-45227. The tlast was noted as observed.
| hours | Cohort 1 (RCC): Ibrutinib 560 mg + Everolimus | Cohort 1 (RCC): Ibrutinib 840 mg + Everolimus | Cohort 2 (UC): Ibrutinib 560 mg + Paclitaxel | Cohort 2 (UC): Ibrutinib 840 mg + Paclitaxel | Cohort 3 (GA): Ibrutinib 560 mg + Docetaxel | Cohort 4 (CRC): Ibrutinib 560 mg + Cetuximab | Cohort 4 (CRC): Ibrutinib 840 mg + Cetuximab |
|---|---|---|---|---|---|---|---|
| Ibrutininb | 15.0 (5.92 to 24.0) | 24.0 (24.0 to 24.0) | 24.0 (6.00 to 24.0) | 24.0 (5.50 to 24.0) | 24.0 (5.75 to 24.0) | 24.0 (5.80 to 24.0) | 24.0 (5.42 to 24.0) |
| PCI-45227 | 15.0 (5.92 to 24.0) | 24.0 (24.0 to 24.0) | 24.0 (6.00 to 24.0) | 24.0 (5.50 to 24.0) | 24.0 (5.85 to 24.0) | 24.0 (24.0 to 24.0) | 24.0 (5.75 to 24.0) |
Actual collection times relative to ibrutinib administration were used for the calculation of pharmacokinetic parameters of ibrutinib and PCI-45227. For actual predose collection times that were \< 0, these values were set equal to 0. Predose concentrations were applied as 24 hour concentrations in order to calculate steady-state (Cycle 2 Day 1) pharmacokinetic parameters for ibrutinib and PCI-45227. The AUC0-24h was calculated by the linear trapezoidal method.
| ng∙h/mL | Cohort 1 (RCC): Ibrutinib 560 mg + Everolimus | Cohort 1 (RCC): Ibrutinib 840 mg + Everolimus | Cohort 2 (UC): Ibrutinib 560 mg + Paclitaxel | Cohort 2 (UC): Ibrutinib 840 mg + Paclitaxel | Cohort 3 (GA): Ibrutinib 560 mg + Docetaxel | Cohort 4 (CRC): Ibrutinib 560 mg + Cetuximab | Cohort 4 (CRC): Ibrutinib 840 mg + Cetuximab |
|---|---|---|---|---|---|---|---|
| Ibrutininb | 1467 ± 1793 | 2568 ± 1968 | 2194 ± 3023 | 3503 ± 2613 | 1253 ± 1232 | 980 ± 371 | 2807 ± 1955 |
| PCI-45227 | 646 ± 698 | 1810 ± 945 | 1146 ± 786 | 2604 ± 1435 | 1254 ± 777 | 1527 ± 717 | 2178 ± 1278 |
Actual collection times relative to ibrutinib administration were used for the calculation of pharmacokinetic parameters of ibrutinib and PCI-45227. For actual predose collection times that were \< 0, these values were set equal to 0. Predose concentrations were applied as 24 hour concentrations in order to calculate steady-state (Cycle 2 Day 1) pharmacokinetic parameters for ibrutinib and PCI-45227. The AUClast was calculated by the linear trapezoidal method.
| ng∙h/mL | Cohort 1 (RCC): Ibrutinib 560 mg + Everolimus | Cohort 1 (RCC): Ibrutinib 840 mg + Everolimus | Cohort 2 (UC): Ibrutinib 560 mg + Paclitaxel | Cohort 2 (UC): Ibrutinib 840 mg + Paclitaxel | Cohort 3 (GA): Ibrutinib 560 mg + Docetaxel | Cohort 4 (CRC): Ibrutinib 560 mg + Cetuximab | Cohort 4 (CRC): Ibrutinib 840 mg + Cetuximab |
|---|---|---|---|---|---|---|---|
| Ibrutininb | 1316 ± 1850 | 2568 ± 1968 | 1180 ± 925 | 3227 ± 2452 | 1107 ± 1178 | 847 ± 310 | 2647 ± 1967 |
| PCI-45227 | 548 ± 741 | 1810 ± 945 | 859 ± 744 | 2380 ± 1561 | 1165 ± 803 | 1527 ± 717 | 2178 ± 1278 |
Actual collection times relative to ibrutinib administration were used for the calculation of pharmacokinetic parameters of ibrutinib and PCI-45227. For actual predose collection times that were \< 0, these values were set equal to 0. Predose concentrations were applied as 24 hour concentrations in order to calculate steady-state (Cycle 2 Day 1) pharmacokinetic parameters for ibrutinib and PCI-45227. The apparent t1/2term was calculated by ln(2)/λz, where λz is the apparent elimination rate constant obtained by linear regression of three or more log-transformed data points in the terminal phase (not including Cmax).
| hours | Cohort 1 (RCC): Ibrutinib 560 mg + Everolimus | Cohort 1 (RCC): Ibrutinib 840 mg + Everolimus | Cohort 2 (UC): Ibrutinib 560 mg + Paclitaxel | Cohort 2 (UC): Ibrutinib 840 mg + Paclitaxel | Cohort 3 (GA): Ibrutinib 560 mg + Docetaxel | Cohort 4 (CRC): Ibrutinib 560 mg + Cetuximab | Cohort 4 (CRC): Ibrutinib 840 mg + Cetuximab |
|---|---|---|---|---|---|---|---|
| Ibrutininb | NA ± NA | 6.28 ± 2.35 | 7.24 ± 2.36 | 4.31 ± 1.95 | 5.54 ± 1.75 | NA ± NA | 5.52 ± 1.26 |
| PCI-45227 | NA ± NA | 8.00 ± 0.489 | 5.08 ± 0.304 | 6.79 ± 4.38 | 6.48 ± 2.11 | 8.10 ± NA | 8.02 ± 2.17 |
Actual collection times relative to ibrutinib administration were used for the calculation of pharmacokinetic parameters of ibrutinib and PCI-45227. For actual predose collection times that were \< 0, these values were set equal to 0. Predose concentrations were applied as 24 hour concentrations in order to calculate steady-state (Cycle 2 Day 1) pharmacokinetic parameters for ibrutinib and PCI-45227. The λz is the apparent elimination rate constant obtained by linear regression of three or more log-transformed data points in the terminal phase (not including Cmax).
| 1/h | Cohort 1 (RCC): Ibrutinib 560 mg + Everolimus | Cohort 1 (RCC): Ibrutinib 840 mg + Everolimus | Cohort 2 (UC): Ibrutinib 560 mg + Paclitaxel | Cohort 2 (UC): Ibrutinib 840 mg + Paclitaxel | Cohort 3 (GA): Ibrutinib 560 mg + Docetaxel | Cohort 4 (CRC): Ibrutinib 560 mg + Cetuximab | Cohort 4 (CRC): Ibrutinib 840 mg + Cetuximab |
|---|---|---|---|---|---|---|---|
| Ibrutininb | NA ± NA | 0.125 ± 0.0477 | 0.101 ± 0.0327 | 0.195 ± 0.0902 | 0.135 ± 0.0349 | NA ± NA | 0.132 ± 0.0296 |
| PCI-45227 | — | 0.0870 ± 0.00535 | 0.137 ± 0.00849 | 0.149 ± 0.103 | 0.118 ± 0.0399 | 0.0897 ± NA | 0.0942 ± 0.0336 |
Actual collection times relative to ibrutinib administration were used for the calculation of pharmacokinetic parameters of ibrutinib and PCI-45227. For actual predose collection times that were \< 0, these values were set equal to 0. Predose concentrations were applied as 24 hour concentrations in order to calculate steady-state (Cycle 2 Day 1) pharmacokinetic parameters for ibrutinib and PCI-45227. Apparent total CLss/F (Cycle 2 Day 1) was calculated as dose/AUC0-24h.
| L/h | Cohort 1 (RCC): Ibrutinib 560 mg + Everolimus | Cohort 1 (RCC): Ibrutinib 840 mg + Everolimus | Cohort 2 (UC): Ibrutinib 560 mg + Paclitaxel | Cohort 2 (UC): Ibrutinib 840 mg + Paclitaxel | Cohort 3 (GA): Ibrutinib 560 mg + Docetaxel | Cohort 4 (CRC): Ibrutinib 560 mg + Cetuximab | Cohort 4 (CRC): Ibrutinib 840 mg + Cetuximab |
|---|---|---|---|---|---|---|---|
| Phase 1b: Apparent Total Clearance at Steady-State (CLss/F) for Ibrutinib in Cohorts 1 to 4 | 1103 ± 1370 | 622 ± 647 | 994 ± 1217 | 1067 ± 2742 | 1102 ± 1412 | 645 ± 248 | 595 ± 726 |
Collected over All-Cause Mortality: Maximum time on study (Phase 1b/2 RP2D) was 37.4 months, 44.7 months, 41.9 months, 23.5 months, 17.3 months, 20.1 months for Cohorts 1, 2, 3, 4, 5, 6 respectively. Serious/Other Adverse Events: First dose of study drug to end of treatment + 30 days. Mean time on treatment was: 14.5, 20.1, 16.3, 13.5, 12.8, 11.0, 10.9, 10.4, 15.8, 8.8, 13.5, 7.7, 8.4, 7.8, 9.2 months for the Reporting Groups presented below (from left to right), respectively.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1 (RCC) Phase 1b: Ibrutinib 560 mg + Everolimus | 3/3 (100%) | 2/3 (66.7%) | 3/3 (100%) |
| Cohort 1 (RCC) Phase 1b: Ibrutinib 840 mg + Everolimus | 1/7 (14.3%) | 2/7 (28.6%) | 7/7 (100%) |
| Cohort 1 (RCC) Phase 2: Ibrutinib 840 mg + Everolimus | 22/38 (57.9%) | 18/38 (47.4%) | 34/38 (89.5%) |
| Cohort 2 (UC) Phase 1b: Ibrutinib 560 mg + Paclitaxel | 3/4 (75%) | 2/4 (50%) | 4/4 (100%) |
| Cohort 2 (UC) Phase 1b: Ibrutinib 840 mg + Paclitaxel | 4/10 (40%) | 5/10 (50%) | 10/10 (100%) |
| Cohort 2 (UC) Phase 2: Ibrutinib 840 mg + Paclitaxel | 51/55 (92.7%) | 32/55 (58.2%) | 51/55 (92.7%) |
| Cohort 3 (GA) Phase 1b: Ibrutinib 560 mg + Docetaxel | 13/21 (61.9%) | 15/21 (71.4%) | 20/21 (95.2%) |
| Cohort 3 (GA) Phase 2 (RP2D): Ibrutinib 560 mg + Docetaxel | 17/31 (54.8%) | 12/31 (38.7%) | 26/31 (83.9%) |
| Cohort 4 (CA) Phase 1b: Ibrutinib 560 mg + Cetuximab | 6/8 (75%) | 5/8 (62.5%) | 8/8 (100%) |
| Cohort 4 (CA) Phase 1b: Ibrutinib 840 mg + Cetuximab | 4/12 (33.3%) | 2/12 (16.7%) | 12/12 (100%) |
| Cohort 4 (CA) Phase 2 (RP2D): Ibrutinib 840 mg + Cetuximab | 31/44 (70.5%) | 14/44 (31.8%) | 40/44 (90.9%) |
| Cohort 5 (UC) Phase 1b: Ibrutinib 840 mg | 2/10 (20%) | 3/10 (30%) | 9/10 (90%) |
| Cohort 5 (UC) Phase 2: Ibrutinib 840 mg | 20/33 (60.6%) | 16/33 (48.5%) | 29/33 (87.9%) |
| Cohort 6 (UC) Phase 1b: Ibrutinib 560 mg + Pembrolizumab | 4/17 (23.5%) | 7/17 (41.2%) | 16/17 (94.1%) |
| Cohort 6 (UC) Phase 2: Ibrutinib 560 mg + Pembrolizumab | 3/13 (23.1%) | 3/13 (23.1%) | 7/13 (53.8%) |
| Event | Cohort 1 (RCC) Phase 1b: Ibrutinib 560 mg + Everolimus | Cohort 1 (RCC) Phase 1b: Ibrutinib 840 mg + Everolimus | Cohort 1 (RCC) Phase 2: Ibrutinib 840 mg + Everolimus | Cohort 2 (UC) Phase 1b: Ibrutinib 560 mg + Paclitaxel | Cohort 2 (UC) Phase 1b: Ibrutinib 840 mg + Paclitaxel | Cohort 2 (UC) Phase 2: Ibrutinib 840 mg + Paclitaxel | Cohort 3 (GA) Phase 1b: Ibrutinib 560 mg + Docetaxel | Cohort 3 (GA) Phase 2 (RP2D): Ibrutinib 560 mg + Docetaxel | Cohort 4 (CA) Phase 1b: Ibrutinib 560 mg + Cetuximab | Cohort 4 (CA) Phase 1b: Ibrutinib 840 mg + Cetuximab | Cohort 4 (CA) Phase 2 (RP2D): Ibrutinib 840 mg + Cetuximab | Cohort 5 (UC) Phase 1b: Ibrutinib 840 mg | Cohort 5 (UC) Phase 2: Ibrutinib 840 mg | Cohort 6 (UC) Phase 1b: Ibrutinib 560 mg + Pembrolizumab | Cohort 6 (UC) Phase 2: Ibrutinib 560 mg + Pembrolizumab |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FEBRILE NEUTROPENIABlood and lymphatic system disorders | 0/3 | 0/7 | 0/38 | 0/4 | 1/10 | 1/55 | 7/21 | 4/31 | 0/8 | 0/12 | 0/44 | 0/10 | 0/33 | 0/17 | 0/13 |
| ACUTE CORONARY SYNDROMECardiac disorders | 1/3 | 0/7 | 0/38 | 0/4 | 0/10 | 0/55 | 0/21 | 0/31 | 0/8 | 0/12 | 0/44 | 0/10 | 0/33 | 0/17 | 0/13 |
| CARDIAC FAILURE CONGESTIVECardiac disorders | 1/3 | 0/7 | 0/38 | 0/4 | 0/10 | 0/55 | 0/21 | 0/31 | 0/8 | 0/12 | 0/44 | 0/10 | 0/33 | 0/17 | 0/13 |
| DIARRHOEAGastrointestinal disorders | 1/3 | 1/7 | 0/38 | 0/4 | 0/10 | 1/55 | 0/21 | 1/31 | 0/8 | 0/12 | 0/44 | 0/10 | 0/33 | 0/17 | 0/13 |
| AMYLOIDOSISImmune system disorders | 1/3 | 0/7 | 0/38 | 0/4 | 0/10 | 0/55 | 0/21 | 0/31 | 0/8 | 0/12 | 0/44 | 0/10 | 0/33 | 0/17 | 0/13 |
| RESPIRATORY TRACT INFECTIONInfections and infestations | 1/3 | 1/7 | 0/38 | 0/4 | 0/10 | 0/55 | 0/21 | 1/31 | 0/8 | 0/12 | 0/44 | 0/10 | 0/33 | 0/17 | 0/13 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 1/3 | 0/7 | 1/38 | 0/4 | 0/10 | 0/55 | 0/21 | 0/31 | 0/8 | 1/12 | 0/44 | 0/10 | 0/33 | 0/17 | 0/13 |
| ACUTE KIDNEY INJURYRenal and urinary disorders | 1/3 | 1/7 | 1/38 | 0/4 | 0/10 | 2/55 | 0/21 | 0/31 | 0/8 | 0/12 | 0/44 | 0/10 | 1/33 | 1/17 | 0/13 |
| RENAL FAILURERenal and urinary disorders | 1/3 | 0/7 | 0/38 | 0/4 | 0/10 | 0/55 | 0/21 | 1/31 | 0/8 | 0/12 | 0/44 | 0/10 | 1/33 | 0/17 | 0/13 |
| INTERSTITIAL LUNG DISEASERespiratory, thoracic and mediastinal disorders | 1/3 | 0/7 | 0/38 | 0/4 | 0/10 | 0/55 | 0/21 | 0/31 | 0/8 | 0/12 | 0/44 | 0/10 | 0/33 | 0/17 | 0/13 |
| Event | Cohort 1 (RCC) Phase 1b: Ibrutinib 560 mg + Everolimus | Cohort 1 (RCC) Phase 1b: Ibrutinib 840 mg + Everolimus | Cohort 1 (RCC) Phase 2: Ibrutinib 840 mg + Everolimus | Cohort 2 (UC) Phase 1b: Ibrutinib 560 mg + Paclitaxel | Cohort 2 (UC) Phase 1b: Ibrutinib 840 mg + Paclitaxel | Cohort 2 (UC) Phase 2: Ibrutinib 840 mg + Paclitaxel | Cohort 3 (GA) Phase 1b: Ibrutinib 560 mg + Docetaxel | Cohort 3 (GA) Phase 2 (RP2D): Ibrutinib 560 mg + Docetaxel | Cohort 4 (CA) Phase 1b: Ibrutinib 560 mg + Cetuximab | Cohort 4 (CA) Phase 1b: Ibrutinib 840 mg + Cetuximab | Cohort 4 (CA) Phase 2 (RP2D): Ibrutinib 840 mg + Cetuximab | Cohort 5 (UC) Phase 1b: Ibrutinib 840 mg | Cohort 5 (UC) Phase 2: Ibrutinib 840 mg | Cohort 6 (UC) Phase 1b: Ibrutinib 560 mg + Pembrolizumab | Cohort 6 (UC) Phase 2: Ibrutinib 560 mg + Pembrolizumab |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DIARRHOEAGastrointestinal disorders | 2/3 | 5/7 | 16/38 | 4/4 | 8/10 | 36/55 | 14/21 | 10/31 | 2/8 | 6/12 | 19/44 | 0/10 | 10/33 | 8/17 | 0/13 |
| FATIGUEGeneral disorders | 0/3 | 3/7 | 14/38 | 3/4 | 5/10 | 15/55 | 8/21 | 8/31 | 2/8 | 8/12 | 14/44 | 1/10 | 9/33 | 6/17 | 4/13 |
| ALOPECIASkin and subcutaneous tissue disorders | 0/3 | 0/7 | 0/38 | 3/4 | 3/10 | 15/55 | 6/21 | 8/31 | 1/8 | 0/12 | 3/44 | 0/10 | 0/33 | 0/17 | 0/13 |
| DERMATITIS ACNEIFORMSkin and subcutaneous tissue disorders | 1/3 | 2/7 | 5/38 | 1/4 | 1/10 | 6/55 | 1/21 | 2/31 | 4/8 | 8/12 | 31/44 | 0/10 | 0/33 | 0/17 | 0/13 |
| DECREASED APPETITEMetabolism and nutrition disorders | 0/3 | 4/7 | 13/38 | 2/4 | 7/10 | 18/55 | 8/21 | 10/31 | 3/8 | 5/12 | 9/44 | 4/10 | 8/33 | 1/17 | 1/13 |
| ANAEMIABlood and lymphatic system disorders | 2/3 | 2/7 | 19/38 | 1/4 | 4/10 | 20/55 | 8/21 | 16/31 | 1/8 | 1/12 | 5/44 | 0/10 | 6/33 | 0/17 | 0/13 |
| STOMATITISGastrointestinal disorders | 2/3 | 3/7 | 20/38 | 1/4 | 3/10 | 14/55 | 9/21 | 8/31 | 4/8 | 5/12 | 20/44 | 0/10 | 3/33 | 4/17 | 0/13 |
| OEDEMA PERIPHERALGeneral disorders | 2/3 | 0/7 | 8/38 | 2/4 | 1/10 | 14/55 | 4/21 | 2/31 | 4/8 | 3/12 | 4/44 | 2/10 | 4/33 | 3/17 | 0/13 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 2/3 | 0/7 | 3/38 | 0/4 | 0/10 | 1/55 | 1/21 | 0/31 | 1/8 | 0/12 | 0/44 | 0/10 | 0/33 | 1/17 | 0/13 |
| BLOOD CREATININE INCREASEDInvestigations | 2/3 | 1/7 | 7/38 | 1/4 | 1/10 | 0/55 | 0/21 | 0/31 | 0/8 | 0/12 | 2/44 | 0/10 | 1/33 | 1/17 | 0/13 |
All treated population: all unique participants enrolled and treated in Phase 1b and Phase 2.
| Age, Customized(Participants) | Cohort 1 (RCC): Ibrutinib 560 mg + Everolimus | Cohort 1 (RCC): Ibrutinib 840 mg + Everolimus | Cohort 2 (UC): Ibrutinib 560 mg + Paclitaxel | Cohort 2 (UC): Ibrutinib 840 mg + Paclitaxel | Cohort 3 (GA): Ibrutinib 560 mg + Docetaxel | Cohort 4 (CRC): Ibrutinib 560 mg + Cetuximab | Cohort 4 (CRC): Ibrutinib 840 mg + Cetuximab | Cohort 5 (UC): Ibrutinib 840 mg | Cohort 6 (UC): Ibrutinib 560 mg + Pembrolizumab | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| 18 - 64 years | 1 | 23 | 3 | 21 | 33 | 6 | 25 | 11 | 6 | 129 |
| 65 - 84 years | 2 | 16 | 1 | 35 | 13 | 2 | 25 | 22 | 12 | 128 |
| ≥ 85 years | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 2 | 0 | 5 |
| Sex: Female, Male(Participants) | Cohort 1 (RCC): Ibrutinib 560 mg + Everolimus | Cohort 1 (RCC): Ibrutinib 840 mg + Everolimus | Cohort 2 (UC): Ibrutinib 560 mg + Paclitaxel | Cohort 2 (UC): Ibrutinib 840 mg + Paclitaxel | Cohort 3 (GA): Ibrutinib 560 mg + Docetaxel | Cohort 4 (CRC): Ibrutinib 560 mg + Cetuximab | Cohort 4 (CRC): Ibrutinib 840 mg + Cetuximab | Cohort 5 (UC): Ibrutinib 840 mg | Cohort 6 (UC): Ibrutinib 560 mg + Pembrolizumab | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Female | 1 | 8 | 0 | 8 | 12 | 7 | 21 | 9 | 5 | 71 |
| Male | 2 | 31 | 4 | 51 | 34 | 1 | 29 | 26 | 13 | 191 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1 (RCC): Ibrutinib 560 mg + Everolimus | Cohort 1 (RCC): Ibrutinib 840 mg + Everolimus | Cohort 2 (UC): Ibrutinib 560 mg + Paclitaxel | Cohort 2 (UC): Ibrutinib 840 mg + Paclitaxel | Cohort 3 (GA): Ibrutinib 560 mg + Docetaxel | Cohort 4 (CRC): Ibrutinib 560 mg + Cetuximab | Cohort 4 (CRC): Ibrutinib 840 mg + Cetuximab | Cohort 5 (UC): Ibrutinib 840 mg | Cohort 6 (UC): Ibrutinib 560 mg + Pembrolizumab | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 2 | 4 | 7 | 3 | 0 | 1 | 1 | 18 |
| Not Hispanic or Latino | 3 | 39 | 2 | 55 | 39 | 4 | 50 | 34 | 17 | 243 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Race (NIH/OMB)(Participants) | Cohort 1 (RCC): Ibrutinib 560 mg + Everolimus | Cohort 1 (RCC): Ibrutinib 840 mg + Everolimus | Cohort 2 (UC): Ibrutinib 560 mg + Paclitaxel | Cohort 2 (UC): Ibrutinib 840 mg + Paclitaxel | Cohort 3 (GA): Ibrutinib 560 mg + Docetaxel | Cohort 4 (CRC): Ibrutinib 560 mg + Cetuximab | Cohort 4 (CRC): Ibrutinib 840 mg + Cetuximab | Cohort 5 (UC): Ibrutinib 840 mg | Cohort 6 (UC): Ibrutinib 560 mg + Pembrolizumab | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Asian | 0 | 7 | 0 | 12 | 12 | 2 | 31 | 5 | 0 | 69 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 4 |
| White | 3 | 32 | 4 | 47 | 32 | 5 | 18 | 30 | 16 | 187 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Requests for access to individual participant data from clinical studies conducted by Pharmacyclics LLC, an AbbVie Company, can be submitted through Yale Open Data Access (YODA) Project site at the following link.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Data sharing details ↗ · yoda.yale.edu
Ran from Dec 2015 to primary completion in Aug 2021, 68 months.
Results were first posted in Oct 2022, 1 year 2 months after primary completion. A results delay was requested in Mar 2022.
Of 70 industry-sponsored phase 1/2 interventional studies under Carcinoma, Renal Cell, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 78. This study's 68 months is close to that.
Counting every sponsor, half of 111 studies reached it within 64 months; a quarter within 45 and three quarters within 87.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ibrutinib